The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study.
COVID-19
FDG
Oncology
PET
Pandemic
Staging
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
26
08
2021
accepted:
20
11
2021
pubmed:
9
12
2021
medline:
1
4
2022
entrez:
8
12
2021
Statut:
ppublish
Résumé
To investigate whether the COVID-19 pandemic and national lockdown had an impact on the extent of cancer disease at FDG PET/CT staging as surrogate marker. Retrospective observational study including cancer patients submitted to FDG PET/CT staging from June 1 to October 31, 2020, and June 1 to October 31, 2019, respectively. Data regarding primary tumour, nodal (N) status and number of involved nodal stations, and presence and number of distant metastases (M) were collected. Each scan was classified in limited vs advanced status. Data were aggregated across the study population and tumour type. Bi-weekly frequencies of the observed events were analysed. Six hundred eleven patients were included (240 in 2019 vs 371 in 2020, respectively). A significant increase of advanced disease patients (rate 1.56, P < 0.001), N + or M + patients (rate 1.84 and 2.09, respectively, P < 0.001), and patients with a greater number of involved N stations or M (rate 2.01 and 2.06, respectively, P < 0.001) were found in 2020 compared with data of 2019. Analysis by tumour type showed a significant increase of advanced disease in lymphoma and lung cancer in 2020 compared with 2019 (P < 0.001). In addition, a significant increase of nodal involvement was found in lung, gastro-intestinal, and breast cancers, as well as in lymphoma patients (P < 0.02). A significant increase of distant metastases was found in lung cancers (P = 0.002). Cancer patients with advanced disease at FDG PET/CT staging increased in 2020 compared with 2019, following the national lockdown due to the COVID-19 pandemic, 1.5-fold with a significant increase of patients with N or M involvement. Targeted health interventions are needed to mitigate the effects of the pandemic on patient outcome.
Identifiants
pubmed: 34877609
doi: 10.1007/s00259-021-05629-0
pii: 10.1007/s00259-021-05629-0
pmc: PMC8651274
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1623-1629Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform. 2020;4:1059–71. https://doi.org/10.1200/CCI.20.00134 .
doi: 10.1200/CCI.20.00134
pubmed: 33253013
de Jonge L, Worthington J, van Wifferen F, Iragorri N, Peterse EFP, Lew JB, et al. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. Lancet Gastroenterol Hepatol. 2021. https://doi.org/10.1016/S2468-1253(21)00003-0 .
doi: 10.1016/S2468-1253(21)00003-0
pubmed: 33548185
Oderda M, Calleris G, Falcone M, Fasolis G, Muto G, Oderda G, et al. How uro-oncology has been affected by COVID-19 emergency? Data from Piedmont/Valle d’Aosta Oncological Network. Ital Urol. 2021;88:3–8. https://doi.org/10.1177/0391560320946186 .
doi: 10.1177/0391560320946186
Fabi A, Pugliese P, Falbo PT, Corsi D, Fabbri MA, Vincenzi B, et al. The experience of oncology healthcare providers in the Central Italy during the COVID-19 lockdown. Cancers (Basel). 2020;12:3031. https://doi.org/10.3390/cancers12103031 .
doi: 10.3390/cancers12103031
pmcid: 7603147
Quaquarini E, Saltalamacchia G, Presti D, Caldana G, Tibollo V, Malovini A, et al. Impact of COVID-19 outbreak on cancer patient care and treatment: data from an outpatient oncology clinic in Lombardy (Italy). Cancers (Basel). 2020;12:2941. https://doi.org/10.3390/cancers12102941 .
doi: 10.3390/cancers12102941
Hirschfeld CB, Shaw LJ, Williams MC, Lahey R, Villines TC, Dorbala S, et al. Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world: The INCAPS-COVID Study. JACC Cardiovasc Imaging. 2021. https://doi.org/10.1016/j.jcmg.2021.03.007 .
doi: 10.1016/j.jcmg.2021.03.007
pubmed: 34147434
pmcid: 8374310
Saini KS, de Las HB, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, et al. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020;7:e432–5. https://doi.org/10.1016/S2352-3026(20)30123-X .
doi: 10.1016/S2352-3026(20)30123-X
pubmed: 32339482
pmcid: 7195053
Di Bidino R, Cicchetti A. Impact of SARS-CoV-2 on provided healthcare. Evidence From the Emergency Phase in Italy. Front Public Health. 2020;8:583583. https://doi.org/10.3389/fpubh.2020.583583 .
doi: 10.3389/fpubh.2020.583583
pubmed: 33330324
pmcid: 7719765
Torzilli G, Viganò L, Galvanin J, Castoro C, Quagliuolo V, Spinelli A, et al. A snapshot of elective oncological surgery in Italy during COVID-19 emergency: pearls, pitfalls, and perspectives. Ann Surg. 2020;272:e112–7. https://doi.org/10.1097/SLA.0000000000004081 .
doi: 10.1097/SLA.0000000000004081
pubmed: 32675512
Albano D, Bruno A, Bruno F, Calandri M, Caruso D, Clemente A, et al. Impact of coronavirus disease 2019 (COVID-19) emergency on Italian radiologists: a national survey. Eur Radiol. 2020;30:6635–44. https://doi.org/10.1007/s00330-020-07046-7 .
doi: 10.1007/s00330-020-07046-7
pubmed: 32661585
pmcid: 7358329
Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, et al. Expected medium- and long-term impact of the COVID-19 outbreak in oncology. JCO Glob Oncol. 2021;7:162–72. https://doi.org/10.1200/GO.20.00589 .
doi: 10.1200/GO.20.00589
pubmed: 33529077
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(328):54. https://doi.org/10.1007/s00259-014-2961-x .
doi: 10.1007/s00259-014-2961-x
Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315–40. https://doi.org/10.1148/rg.232025705 (quiz 533).
doi: 10.1148/rg.232025705
Kandathil A, Kay FU, Butt YM, Wachsmann JW, Subramaniam RM. Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non small Cell Lung Cancer. Radiographics. 2018;38:2134–49. https://doi.org/10.1148/rg.2018180060 .
doi: 10.1148/rg.2018180060
pubmed: 30422775
Wartski M, Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging. 2019;100:735–41. https://doi.org/10.1016/j.diii.2019.07.006 .
doi: 10.1016/j.diii.2019.07.006
pubmed: 31402332
Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol. 2019;21:1–10. https://doi.org/10.1007/s11307-018-1181-3 .
doi: 10.1007/s11307-018-1181-3
pubmed: 29516387
Ha HK, Koo PJ, Kim SJ. Diagnostic accuracy of F-18 FDG PET/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis. Oncology. 2018;95:31–8. https://doi.org/10.1159/000488200 .
doi: 10.1159/000488200
pubmed: 29847834
CaresiaAroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, et al. 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 2017;39:1010428317728285. https://doi.org/10.1177/1010428317728285 .
doi: 10.1177/1010428317728285
Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in staging, response evaluation, and surveillance of lymphoma. Curr Treat Options Oncol. 2016;17:24. https://doi.org/10.1007/s11864-016-0399-z .
doi: 10.1007/s11864-016-0399-z
pubmed: 27032646
Perng P, Marcus C, Subramaniam RM. (18)F-FDG PET/CT and melanoma: staging, immune modulation and mutation-targeted therapy assessment, and prognosis. AJR Am J Roentgenol. 2015;205:259–70. https://doi.org/10.2214/AJR.14.13575 .
doi: 10.2214/AJR.14.13575
pubmed: 26204273
Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81. https://doi.org/10.1245/s10434-015-4391-9 .
doi: 10.1245/s10434-015-4391-9
pubmed: 25652048
Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56:523–9. https://doi.org/10.2967/jnumed.114.150946 .
doi: 10.2967/jnumed.114.150946
pubmed: 25745094
Mak D, Corry J, Lau E, Rischin D, Hicks RJ. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging. 2011;55:487–99.
pubmed: 22019706
Yousefi-Koma A, Panah-Moghaddam M, Kalff V. The utility of metabolic imaging by 18F-FDG PET/CT in lung cancer: impact on diagnosis and staging. Tanaffos. 2013;12:16–25.
pubmed: 25191445
pmcid: 4153235
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (editors). AJCC cancer staging manual. 8th ed. Springer International Publishing; 2017.
Wang X. Firth logistic regression for rare variant association tests. Front Genet. 2014;5:187. https://doi.org/10.3389/fgene.2014.00187 .
doi: 10.3389/fgene.2014.00187
pubmed: 24995013
pmcid: 4063169
Jereczek-Fossa BA, Pepa M, Marvaso G, Bruni A, Buglione di Monale E, Bastia M, Catalano G, et al. COVID-19 outbreak and cancer radiotherapy disruption in Italy: survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiother Oncol. 2020;149:89–93. https://doi.org/10.1016/j.radonc.2020.04.061 .
doi: 10.1016/j.radonc.2020.04.061
pubmed: 32413527
pmcid: 7215158
Oldani C, Vanni G, Buonomo OC. COVID-19 unintended effects on breast cancer in Italy after the great lockdown. Front Public Health. 2020;8: 601748. https://doi.org/10.3389/fpubh.2020.601748 .
doi: 10.3389/fpubh.2020.601748
pubmed: 33425839
pmcid: 7786396
Fortunato L, d’Amati G, Taffurelli M, Tinterri C, Marotti L, Cataliotti L. Severe impact of Covid-19 pandemic on breast cancer care in Italy: a Senonetwork national survey. Clin Breast Cancer. 2020. https://doi.org/10.1016/j.clbc.2020.10.012 .
doi: 10.1016/j.clbc.2020.10.012
pubmed: 33744100
Rebecchi F, Arolfo S, Ugliono E, Morino M, Asti E, Bonavina L, et al. Impact of COVID-19 outbreak on esophageal cancer surgery in Northern Italy: lessons learned from a multicentric snapshot. Dis Esophagus. 2020. https://doi.org/10.1093/dote/doaa124 .
doi: 10.1093/dote/doaa124
Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, Cancer care during the spread of coronavirus disease, et al. (COVID-19) in Italy: young oncologists’ perspective. ESMO Open. 2019;2020:5. https://doi.org/10.1136/esmoopen-2020-000759 .
doi: 10.1136/esmoopen-2020-000759
https://www.agenas.gov.it/covid19/web/index.php?r=site%2Fresilienza . 2021.
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371: m4087. https://doi.org/10.1136/bmj.m4087 .
doi: 10.1136/bmj.m4087
pubmed: 33148535
Gheorghe A, Maringe C, Spice J, Purushotham A, Chalkidou K, Rachet B, et al. Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: a national population-based modelling study in England. UK Eur J Cancer. 2021. https://doi.org/10.1016/j.ejca.2021.04.019 .
doi: 10.1016/j.ejca.2021.04.019
pubmed: 34049776
Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023–34. https://doi.org/10.1016/S1470-2045(20)30388-0 .
doi: 10.1016/S1470-2045(20)30388-0
pubmed: 32702310
pmcid: 7417808
Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035–44. https://doi.org/10.1016/S1470-2045(20)30392-2 .
doi: 10.1016/S1470-2045(20)30392-2
pubmed: 32702311
pmcid: 7116538
Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707–14. https://doi.org/10.1097/00006231-200008000-00002 .
doi: 10.1097/00006231-200008000-00002
pubmed: 11039452